FDA clears mini transducer capable of creating 3D ultrasound images

The U.S. Food and Drug Administration (FDA) has cleared a mini transesophageal echocardiography (TEE) transducer, capable of producing high-quality 3D ultrasound images of the heart. 

The X11-4t Mini from Philips Healthcare is 35% smaller than traditional models, designed to allow for easier cardiac scans with less strain on operators without sacrificing quality. The transducer is especially useful for pediatric care. 

The smaller design makes 3D images possible in complex care situations where typically only 2D options were available because of the size of the transducer.

“That’s why we’ve developed a new, even smaller mini 3D TEE transducer that can be used to help physicians serve a wider range of patients, from small children to fragile adults,” David Handler, the vice president and general manager of Philips cardiology ultrasound added in a statement. “With this innovation we can help reduce the need for general anesthesia and lower the risk of complications, meaning patients may recover faster from procedures and can be discharged sooner.”

The mini device will seamlessly integrate into existing Philips EPIQ cardiac ultrasound systems, and it’s set to be commercially available in the U.S. this year. Approval in Europe is pending. 

Chad Van Alstin Health Imaging Health Exec

Chad is an award-winning writer and editor with over 15 years of experience working in media. He has a decade-long professional background in healthcare, working as a writer and in public relations.

Around the web

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.